Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis
Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis
复制标题
DOI：
10.1007/s10165-012-0660-7
复制
发表时间：
2013-03-01
影响因子：
2.2
通讯作者：
Kadono, Takafumi
中科院分区：
文献类型：
--
作者：
Masui, Yuri;Asano, Yoshihide;Kadono, Takafumi
探讨系统性硬化症（SSc）合并间质性肺疾病（ILD）患者静脉注射环磷酰胺（IVCY）期间监测血清脂联素水平的临床意义。采用特异性酶联免疫吸附法测定8例SSc伴活动性ILD的IVCY患者和27例健康对照者的血清脂联素水平。患者在每次IVCY的前一天抽取血清样本。SSc合并活动性ILD患者首次IVCY前血清脂联素水平显著低于健康对照组[中位数（25-75百分位数）：3.21（2.70-4.19）比7.42 (6.06-10.82)μ g/ml；P < 0.01)。全IVCY完成后，血清脂联素水平显著升高[17.55 (6.47 ~ 39.45)mu g/ml；P < 0.05]，且升高与ILD评分降低显著相关。重要的是，IVCY治疗期间血清脂联素水平的动态反映了其在治疗和随访期间对SSc-ILD的疗效。在IVCY治疗期间监测血清脂联素水平可能有助于识别难治性ILD的SSc患者，并在随访期间处于恶化的高风险。
To investigate the clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide (IVCY) in systemic sclerosis (SSc) patients with interstitial lung disease (ILD).Serum adiponectin levels were determined by a specific enzyme-linked immunosorbent assay in eight SSc patients with active ILD who underwent IVCY and 27 healthy controls. In patients, serum samples were drawn the day before each IVCY.Serum adiponectin levels were significantly decreased in SSc patients with active ILD before the first IVCY compared with healthy controls [median (25-75 percentile): 3.21 (2.70-4.19) vs. 7.42 (6.06-10.82) mu g/ml; P < 0.01). After the completion of whole IVCY, serum adiponectin levels were significantly increased [17.55 (6.47-39.45) mu g/ml; P < 0.05] compared with the initial levels, and this increase significantly correlated with the decrease in ILD scores. Importantly, the dynamics of serum adiponectin levels during the IVCY therapy reflected its efficacy against SSc-ILD over the treatment and the follow-up period.The monitoring of serum adiponectin levels during the IVCY treatment may be useful to identify SSc patients with ILD refractory to the treatment and at high risk for exacerbations during the follow-up period.